Confidence in China's Economy | Jia Shaojun, Executive President and Board member of AIM Vaccine: Innovative Measures Enable Private Enterprises to Improve Quality and Efficiency
Jia Shaojun, Executive President and Board member of AIM Vaccine, introduced three important characters of vaccine biologics. First, it has high technology barrier and needs high-level talents and cutting-edge technology. Second, it has a long product cycle. It takes five to eight years from R&D to market launch for a vaccine product and some products may even take more than ten years. Third, it demands for huge investment in terms of R&D and infrastructure. In his view, the fundamental solution for vaccine companies to solve technological challenges is to build a team of high-level talents which requires long-term investment.
Jia Shaojun mentioned during the interview that the confidence of AIM Vaccine comes from China’s support for the development of private enterprises, which allows them to invest and make long-term plans. In terms of political environment, AIM Vaccine currently has three research institutes, four R&D centers and four vaccine manufacturing companies in Ningbo, Taizhou and Dalian. Thanks to the support from local policies, the company has achieved steady development. In terms of technological innovation, AIM Vaccine has seen significant increase in investment and criteria setting in recent years’ system construction. “In terms of product R&D, a transparent and standardized audit system has been established via the reform over the past few years. In terms of production, vaccine quality can be guaranteed with the measures of environmental supervision and unannounced inspection by national and provincial FDA, on-site inspection by inspectors and real-time data upload," said Jia Shaojun. He also said that China's vaccine industry is now ready for development to the next level.